Financial Counselors Inc. Sells 1,859 Shares of Stryker Co. (NYSE:SYK)

Financial Counselors Inc. reduced its holdings in Stryker Co. (NYSE:SYK - Free Report) by 4.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,511 shares of the medical technology company's stock after selling 1,859 shares during the quarter. Financial Counselors Inc.'s holdings in Stryker were worth $13,146,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Murphy & Mullick Capital Management Corp acquired a new position in shares of Stryker in the 4th quarter worth $111,000. Mitsubishi UFJ Trust & Banking Corp increased its stake in Stryker by 3.1% in the 4th quarter. Mitsubishi UFJ Trust & Banking Corp now owns 169,467 shares of the medical technology company's stock worth $61,017,000 after purchasing an additional 5,039 shares in the last quarter. PKS Advisory Services LLC acquired a new stake in Stryker during the 4th quarter worth about $904,000. Prestige Wealth Management Group LLC lifted its stake in Stryker by 5.5% during the fourth quarter. Prestige Wealth Management Group LLC now owns 957 shares of the medical technology company's stock valued at $345,000 after buying an additional 50 shares in the last quarter. Finally, Heritage Wealth Management Inc. CA boosted its holdings in shares of Stryker by 4,802.0% in the fourth quarter. Heritage Wealth Management Inc. CA now owns 2,451 shares of the medical technology company's stock worth $883,000 after buying an additional 2,401 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

SYK has been the subject of several research analyst reports. Canaccord Genuity Group upped their price target on shares of Stryker from $420.00 to $435.00 and gave the company a "buy" rating in a research report on Wednesday, January 29th. Royal Bank of Canada increased their target price on Stryker from $425.00 to $435.00 and gave the company an "outperform" rating in a report on Wednesday, January 29th. JPMorgan Chase & Co. boosted their price target on shares of Stryker from $420.00 to $445.00 and gave the company an "overweight" rating in a report on Wednesday, January 29th. Citigroup reiterated a "buy" rating and set a $450.00 price objective on shares of Stryker in a report on Wednesday, February 26th. Finally, JMP Securities restated a "market perform" rating on shares of Stryker in a research note on Tuesday, February 18th. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $421.90.

Remove Ads

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 201,392 shares of the firm's stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares of the company's stock, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by corporate insiders.

Stryker Stock Performance

Shares of NYSE SYK traded down $3.16 during trading hours on Friday, hitting $364.38. 1,274,307 shares of the company's stock were exchanged, compared to its average volume of 1,289,456. The company's 50-day moving average price is $384.08 and its 200-day moving average price is $374.32. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19. The stock has a market capitalization of $139.08 billion, a price-to-earnings ratio of 46.96, a PEG ratio of 2.93 and a beta of 0.95. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts' consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter last year, the firm earned $3.46 earnings per share. On average, sell-side analysts expect that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.92%. The ex-dividend date of this dividend is Monday, March 31st. Stryker's dividend payout ratio is currently 43.30%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.